Anti-mycobacterial therapy + immunomodulatory treatment
Anti-mycobacterial therapy + immunomodulatory treatment has been studied in 1 paper since 2026: none in people yet; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 11, 2026: “Disseminated Mycobacterium avium Complex–Associated Hemophagocytic Lymphohistiocytosis Revealing GATA2 Deficiency and Clonal Hematopoiesis: A Case Report and Literature Review”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1 papers on anti-mycobacterial therapy + immunomodulatory treatment
At a glance
The findings reach people, from one lab or study. 1 lab.
“Anti-mycobacterial therapy together with immunomodulatory treatment resulted in defervescence, regression of lymphadenopathy and skin lesions, and improvement in HLH-associated inflammatory markers”
None of its findings points the other way.
- 1 lab
What did studies of anti-mycobacterial therapy + immunomodulatory treatment find?
2Studies of anti-mycobacterial therapy + immunomodulatory treatment measured 2 outcomes: HLH-associated inflammatory markers and fever.
HLH-associated inflammatory markers
downin humans1
1 study
HLH-associated inflammatory markers
downin humans1
Anti-mycobacterial therapy + immunomodulatory treatment is linked with lower HLH-associated inflammatory markers in humans.
“Anti-mycobacterial therapy together with immunomodulatory treatment resulted in defervescence, regression of lymphadenopathy and skin lesions, and improvement in HLH-associated inflammatory markers”
HumansDisseminated Mycobacterium avium complex infection and secondary hemophagocytic lymphohistiocytosis with GATA2 deficiencymalesn = 1
Frontiers in immunology
Fever
downin humans1
1 study
Fever
downin humans1
Anti-mycobacterial therapy + immunomodulatory treatment is linked with lower fever in humans.
“Anti-mycobacterial therapy together with immunomodulatory treatment resulted in defervescence, regression of lymphadenopathy and skin lesions, and improvement in HLH-associated inflammatory markers”
HumansDisseminated Mycobacterium avium complex infection and secondary hemophagocytic lymphohistiocytosis with GATA2 deficiencymalesn = 1
Frontiers in immunology